MX361458B - Compuestos de pirimido-piridazinona y uso de los mismos. - Google Patents

Compuestos de pirimido-piridazinona y uso de los mismos.

Info

Publication number
MX361458B
MX361458B MX2014002112A MX2014002112A MX361458B MX 361458 B MX361458 B MX 361458B MX 2014002112 A MX2014002112 A MX 2014002112A MX 2014002112 A MX2014002112 A MX 2014002112A MX 361458 B MX361458 B MX 361458B
Authority
MX
Mexico
Prior art keywords
compounds
pyrimido
pyridazinone compounds
pyridazinone
novel pyrimido
Prior art date
Application number
MX2014002112A
Other languages
English (en)
Other versions
MX2014002112A (es
Inventor
Aranapakam Venkatesan
Roger Astbury Smith
Subramanya Hosahalli
Vijay Potluri
Sunil Kumar Panigrahi
Vishnu Basetti
Karunasree Kuntu
Original Assignee
Asana Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asana Biosciences Llc filed Critical Asana Biosciences Llc
Publication of MX2014002112A publication Critical patent/MX2014002112A/es
Publication of MX361458B publication Critical patent/MX361458B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente solicitud proporciona novedosos compuestos de dirimido-piridazinona y métodos para preparar y usar estos compuestos; estos compuestos son útiles en el tratamiento de la inflamación en pacientes por medio de la administración de uno o más de los compuestos a un paciente; en una modalidad, el novedoso compuesto de dirimido-piridazinona es de la fórmula (I) y R1 y R2 son como se definen en la presente.
MX2014002112A 2011-08-23 2012-08-23 Compuestos de pirimido-piridazinona y uso de los mismos. MX361458B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161526525P 2011-08-23 2011-08-23
PCT/US2012/051980 WO2013028818A1 (en) 2011-08-23 2012-08-23 Pyrimido- pyridazinone compounds and use thereof

Publications (2)

Publication Number Publication Date
MX2014002112A MX2014002112A (es) 2014-09-25
MX361458B true MX361458B (es) 2018-12-06

Family

ID=46829884

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002112A MX361458B (es) 2011-08-23 2012-08-23 Compuestos de pirimido-piridazinona y uso de los mismos.

Country Status (14)

Country Link
US (5) US8729079B2 (es)
EP (4) EP4327886A3 (es)
JP (1) JP5993010B2 (es)
CN (2) CN108707151B (es)
BR (1) BR112014003981A2 (es)
CA (1) CA2846187A1 (es)
DK (2) DK3392252T3 (es)
ES (2) ES2690971T3 (es)
FI (1) FI3392252T3 (es)
HU (1) HUE065564T2 (es)
IL (1) IL231082A (es)
MX (1) MX361458B (es)
PL (1) PL2748166T3 (es)
WO (1) WO2013028818A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3392252T3 (da) * 2011-08-23 2024-01-08 Libertas Bio Inc Pyrimido-pyridazinonforbindelser og deres anvendelse
AR106830A1 (es) * 2015-12-04 2018-02-21 Asana Biosciences Llc Usos de piridazinonas para tratar el cáncer
WO2018187294A1 (en) * 2017-04-03 2018-10-11 Asana Biosciences, Llc Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof
CN110809471A (zh) * 2017-04-28 2020-02-18 阿沙纳生物科学公司 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
CN111961035B (zh) * 2019-05-20 2022-11-01 南京科技职业学院 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用
WO2021027943A1 (zh) * 2019-08-14 2021-02-18 正大天晴药业集团南京顺欣制药有限公司 哒嗪酮并嘧啶类衍生物及其医药用途
CN113583026B (zh) * 2020-04-30 2024-06-14 杭州英创医药科技有限公司 一类含有稠合三环结构的化合物
CN115916747A (zh) * 2020-07-01 2023-04-04 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
CA3240772A1 (en) * 2021-12-22 2023-06-29 Kevan M. Shokat Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase
US20250171448A1 (en) 2022-02-23 2025-05-29 Teva Pharmaceuticals International Gmbh Solid state forms of gusacitinib
US20260055079A1 (en) * 2022-04-01 2026-02-26 Azkarra Therapeutics, Inc. Phthalazinone compounds as parp7 inhibitors
WO2025024765A1 (en) 2023-07-27 2025-01-30 Libertas Bio, Inc. Solid state forms of gusacitinib
WO2025020171A1 (en) * 2023-07-27 2025-01-30 Libertas Bio, Inc. Crystalline forms of a jak/syk inhibitor

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE756508A (fr) * 1969-09-24 1971-03-01 Takeda Chemical Industries Ltd Derives de pyrimidopyridazine
CA1004223A (en) * 1972-05-12 1977-01-25 Theodor Denzel Amino derivatives of pyrido(2,3-d)pyridazine carboxylic acids and esters
JPS4948695U (es) 1972-07-29 1974-04-27
JPS50101387A (es) * 1974-01-16 1975-08-11
CA1052046A (en) 1974-01-21 1979-04-03 American Cyanamid Company Unsymmetrically substituted 1,4-dioxane-2,5-diones
US5369086A (en) 1993-04-28 1994-11-29 Zeneca Limited N-benzotriazoles
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
JPH0948695A (ja) 1995-08-02 1997-02-18 Toshiba Ceramics Co Ltd シリコン単結晶の製造方法
AU3180999A (en) 1998-02-25 1999-09-15 Pharmacia & Upjohn Company Substituted aminomethyl isoxazoline derivatives useful as antimicrobials
SK287269B6 (sk) 1998-11-10 2010-05-07 Janssen Pharmaceutica N. V. Derivát pyrimidínu, jeho použitie, spôsob jeho prípravy a farmaceutická kompozícia, kombinácia a produkt s jeho obsahom
EP1322651B1 (en) * 2000-09-22 2008-01-23 N.V. Organon Bicyclic heteroaromatic compounds
CA2446514A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
WO2003075828A2 (en) 2002-03-11 2003-09-18 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
US20040242568A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
JP4886511B2 (ja) 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ, インコーポレイテッド 2,4−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
TW200538120A (en) 2004-02-20 2005-12-01 Kirin Brewery Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same
BRPI0516746A (pt) 2004-09-30 2008-09-23 Tibotec Pharm Ltd 5-heterociclil pirimidinas para inibição de hiv
CN102861019B (zh) 2004-12-24 2016-05-25 诺华股份有限公司 治疗或预防神经性疼痛的药物
AU2006226322B2 (en) 2005-03-25 2012-03-29 Tibotec Pharmaceuticals Ltd. Heterobicylic inhibitors of HCV
ES2369282T3 (es) 2005-03-25 2011-11-29 Tibotec Pharmaceuticals Inhibidores heterobicíclicos de vhc.
KR20080000584A (ko) 2005-04-29 2008-01-02 얀센 파마슈티카 엔.브이. 카나비노이드 수용체 길항제로서의 벤조트리아졸 유도체
EP1970373A1 (en) * 2005-12-02 2008-09-17 Mitsubishi Tanabe Pharma Corporation Alicyclic heterocyclic compound
WO2007082131A1 (en) 2006-01-09 2007-07-19 Bristol-Myers Squibb Company Process for the preparation of hydroxy substituted heterocycles
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
GB0625196D0 (en) 2006-12-18 2007-01-24 7Tm Pharma As Modulators of cannabinoid receptor
DK2120579T3 (da) * 2006-12-28 2014-02-03 Abbvie Inc Inhibitorer af poly(ADP-ripose)polymerase
JP5577104B2 (ja) 2007-03-14 2014-08-20 エクセリクシス パテント カンパニー エルエルシー ヘッジホッグ経路の阻害剤
TW200938542A (en) * 2008-02-01 2009-09-16 Irm Llc Compounds and compositions as kinase inhibitors
JP2012504157A (ja) * 2008-09-30 2012-02-16 アストラゼネカ アクチボラグ 複素環式jakキナーゼ阻害剤
UY32158A (es) 2008-10-03 2010-04-30 Astrazeneca Ab Derivados heterociclicos y metodos de uso de los mismos
JP2012506386A (ja) 2008-10-21 2012-03-15 メタボレックス, インコーポレイテッド アリールgpr120受容体アゴニストおよびその使用
ES2658290T3 (es) * 2009-10-29 2018-03-09 Genosco Inhibidores de cinasa
WO2011079105A1 (en) * 2009-12-23 2011-06-30 Abbott Laboratories Novel thienopyrrole compounds
WO2012058671A1 (en) 2010-10-31 2012-05-03 Endo Pharmaceuticals Inc. Substituted quinazoline and pyrido-pyrimidine derivatives
DK3392252T3 (da) * 2011-08-23 2024-01-08 Libertas Bio Inc Pyrimido-pyridazinonforbindelser og deres anvendelse
TW201410657A (zh) 2012-08-02 2014-03-16 Endo Pharmaceuticals Inc 經取代胺基-嘧啶衍生物
AR106830A1 (es) * 2015-12-04 2018-02-21 Asana Biosciences Llc Usos de piridazinonas para tratar el cáncer
CN110809471A (zh) * 2017-04-28 2020-02-18 阿沙纳生物科学公司 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型

Also Published As

Publication number Publication date
PL2748166T3 (pl) 2019-05-31
DK3392252T3 (da) 2024-01-08
DK2748166T3 (en) 2018-10-29
EP2748166B1 (en) 2018-07-11
US9382277B2 (en) 2016-07-05
JP5993010B2 (ja) 2016-09-14
ES2690971T3 (es) 2018-11-23
CN103974955B (zh) 2018-06-19
EP4327886A2 (en) 2024-02-28
EP4327886A3 (en) 2024-05-22
CA2846187A1 (en) 2013-02-28
US10183944B2 (en) 2019-01-22
US20160257691A1 (en) 2016-09-08
WO2013028818A1 (en) 2013-02-28
IL231082A (en) 2016-09-29
US20140221315A1 (en) 2014-08-07
CN108707151A (zh) 2018-10-26
JP2014524475A (ja) 2014-09-22
CN103974955A (zh) 2014-08-06
EP3404029A2 (en) 2018-11-21
US8729079B2 (en) 2014-05-20
CN108707151B (zh) 2022-06-03
US20130053346A1 (en) 2013-02-28
WO2013028818A8 (en) 2013-09-19
ES2969977T3 (es) 2024-05-23
EP3392252A1 (en) 2018-10-24
BR112014003981A2 (pt) 2017-03-07
EP3404029A3 (en) 2018-12-12
FI3392252T3 (fi) 2024-01-08
EP3392252B1 (en) 2023-10-04
US20200190095A1 (en) 2020-06-18
EP2748166A1 (en) 2014-07-02
US10647720B2 (en) 2020-05-12
IL231082A0 (en) 2014-03-31
HUE065564T2 (hu) 2024-06-28
MX2014002112A (es) 2014-09-25
US20190092779A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
MX361458B (es) Compuestos de pirimido-piridazinona y uso de los mismos.
PH12014500164A1 (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
AU2016202535B2 (en) Fused heterocyclic compounds as sodium channel modulators
MX338916B (es) Oxazepinas como moduladores del canal de iones.
NZ609309A (en) Redox drug derivatives
NZ709211A (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
EA201390381A1 (ru) Триазиноксадиазолы
PH12014500257A1 (en) Inhibitors of influenza viruses replication
EA201301154A1 (ru) Разветвленные производные 3-фенилпропионовой кислоты и их применение
EA201590453A1 (ru) Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
MX377157B (es) Preparación para usarse en el tratamiento de un cáncer positivo de gd2.
BR112012023021A2 (pt) compostos de indazol e seus usos
MX2013006846A (es) Inhibidores de la replicacion de los virus de la influenza.
IN2014MN01755A (es)
MA33939B1 (fr) 5-alcynyl-pyrimidines
MX348961B (es) Compuestos de aminoindano y su uso en el tratamiento del dolor.
MX2014008021A (es) Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor.
MX2015003021A (es) Derivados de acido glicirretinico y metodos de uso de los mismos.
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
UA107562C2 (uk) Спосіб лікування псоріазу
MX390763B (es) Compuestos de tetraciclina
MX2014003701A (es) Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio.
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
TN2015000095A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
EA201300408A1 (ru) Производные фенилхиназолина

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ASANA BIOSCIENCES, LLC

FG Grant or registration